Ngenla, developed by Pfizer in partnership with OPKO Health, is a long-acting growth hormone therapy that requires only one injection per week — a meaningful change for families who have managed daily injection schedules for years. This page explains what Ngenla is, how it works, what the clinical research shows, and the questions worth raising with your physician.
Ngenla (active ingredient: somatrogon-ghla) is a long-acting recombinant growth hormone product administered as a single injection once per week. It was developed by Pfizer in partnership with OPKO Health and received approval from the U.S. Food and Drug Administration on June 28, 2023, for the treatment of growth failure due to inadequate secretion of endogenous growth hormone in pediatric patients three years of age and older.
Before its U.S. approval, Ngenla had already been authorized by regulators in Canada (2021), Japan (2022), the European Union (2022), Australia and the United Kingdom — making it one of the first long-acting pediatric growth hormone therapies to reach the global market.
Traditional recombinant growth hormone products are bioidentical to the natural hormone produced by the pituitary gland. Because that natural hormone has a very short half-life in the body, conventional therapy has historically required a small subcutaneous injection every night.
Ngenla takes a different molecular approach. It is a fusion protein that combines a growth hormone molecule with three copies of the C-terminal peptide (CTP) from human chorionic gonadotropin. This CTP modification — the same approach used in some long-acting fertility medications — slows the protein's clearance from the body. The practical result is that one weekly dose maintains growth-supporting hormone activity throughout the dosing interval.
For families, this means fewer than 60 injections per year instead of more than 300.
The FDA approved Ngenla specifically for pediatric patients three years of age and older with growth failure due to inadequate secretion of endogenous growth hormone — clinically known as growth hormone deficiency (GHD).
It is not currently FDA-approved in the U.S. for the other pediatric indications that some daily growth hormone products carry — such as Idiopathic Short Stature (ISS), Turner Syndrome, Small for Gestational Age (SGA), Prader-Willi Syndrome or chronic kidney disease in children. Patients with these conditions remain on daily growth hormone protocols unless their physician makes an off-label decision after thorough discussion with the family.
The pivotal Phase 3 study supporting Ngenla's approval was the heiGHt trial, a global, randomized, open-label, active-controlled study comparing once-weekly somatrogon to daily somatropin (Genotropin) in treatment-naïve prepubertal children with growth hormone deficiency.
An important nuance: while overall growth was equivalent, the pattern of IGF-1 release across the week is different — concentrations peak in the days immediately following injection and trough toward the end of the week. Long-term safety registries are continuing to evaluate this pattern, and physicians monitor IGF-1 timing when assessing dose.
The safety profile of Ngenla observed in clinical trials and post-marketing surveillance has been generally similar to that of daily growth hormone, which has more than 40 years of established pediatric safety data. Reported side effects in the heiGHt trial included:
As with any growth hormone product, ongoing physician monitoring — typically every 3 to 6 months including blood work, height/weight measurements and bone age assessment — is essential.
Whether Ngenla is the right choice for any specific child is a clinical decision that depends on multiple factors. Conversations with your physician will typically consider:
Ngenla is FDA-approved for pediatric growth hormone deficiency (GHD). Children with other approved indications such as ISS or Turner Syndrome are typically managed with daily therapy.
Families who have struggled with consistent daily injections — due to schedule, child preference, travel or caregiver logistics — may benefit significantly from a once-weekly option.
As a newer therapy, Ngenla is still being adopted across pediatric practices. Some physicians prefer to start with familiar daily protocols; others actively offer the weekly option.
The list price of Ngenla is set by Pfizer and varies based on the dose required (which is weight-based) and the supply duration. As with all growth hormone products, the actual out-of-pocket cost a family pays depends heavily on:
For families working with one of HGHKids.com's partner cash-pay clinics, treatment costs — whether for Ngenla or any other physician-prescribed therapy — are discussed transparently and privately during the consultation. Ongoing treatment costs are determined by your physician based on the prescribed protocol and your child's individual needs.
HGHKids.com is an educational and referral platform — we do not set prices, sell medication or determine which therapy a physician will recommend. Our partner clinics are private cash-pay practices. The initial evaluation is approximately $2,000 and ongoing treatment costs are discussed privately with the physician based on what's clinically appropriate for your child.
If you're considering Ngenla — either for a child starting growth hormone therapy for the first time, or as a switch from daily therapy — a productive conversation with your physician might cover:
Ngenla is part of a broader shift in pediatric endocrine care toward long-acting hormone therapies. Other once-weekly growth hormone products have also reached the market in recent years, and adoption is steadily increasing as physicians become more familiar with the dosing patterns and as long-term safety data accumulates.
For families who have spent years administering nightly injections, the prospect of a single weekly dose is significant. For physicians, the choice between weekly and daily protocols is now one more variable to optimize alongside dose, brand and monitoring schedule. Whatever option a family ultimately uses, the most important factors for outcome remain unchanged: early diagnosis, consistent adherence and ongoing physician oversight.
This article draws from publicly available information including the FDA approval announcement (June 2023), the published heiGHt trial results, and Pfizer's prescribing information for Ngenla. For full prescribing information, including a complete list of warnings, contraindications, and adverse events, refer to the official Ngenla labeling provided by Pfizer or consult your child's physician.
Whether your family is exploring growth hormone therapy for the first time or weighing options like Ngenla against current treatment, our partner physicians can provide a thorough evaluation.
Medical disclaimer: Ngenla® is a registered trademark of Pfizer Inc. HGHKids.com is independent and not affiliated with, endorsed by, or sponsored by Pfizer or OPKO Health. This page is for general educational purposes only and is not medical advice. All information regarding any therapy, including FDA-approved indications, dosing, efficacy, and safety, should be confirmed with your child's treating physician and the official prescribing information.